Travel habits and complications in patients treated with vitamin K antagonists: A cross sectional analysis
Standard
Travel habits and complications in patients treated with vitamin K antagonists: A cross sectional analysis. / Ringwald, Juergen; Lehmann, Marina; Niemeyer, Nicole; Seifert, Isabell; Daubmann, Anne; Wegscheider, Karl; Salzwedel, Annett; Luxembourg, Beate; Eckstein, Reinhold; Voeller, Heinz.
In: TRAVEL MED INFECT DI, Vol. 12, No. 3, 2014, p. 258-63.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Travel habits and complications in patients treated with vitamin K antagonists: A cross sectional analysis
AU - Ringwald, Juergen
AU - Lehmann, Marina
AU - Niemeyer, Nicole
AU - Seifert, Isabell
AU - Daubmann, Anne
AU - Wegscheider, Karl
AU - Salzwedel, Annett
AU - Luxembourg, Beate
AU - Eckstein, Reinhold
AU - Voeller, Heinz
N1 - Copyright © 2014 Elsevier Ltd. All rights reserved.
PY - 2014
Y1 - 2014
N2 - BACKGROUND: Travel-related conditions have impact on the quality of oral anticoagulation therapy (OAT) with vitamin K-antagonists. No predictors for travel activity and for travel-associated haemorrhage or thromboembolic complications of patients on OAT are known.METHODS: A standardised questionnaire was sent to 2500 patients on long-term OAT in Austria, Switzerland and Germany. 997 questionnaires were received (responder rate 39.9%). Ordinal or logistic regression models with travel activity before and after onset of OAT or travel-associated haemorrhages and thromboembolic complications as outcome measures were applied.RESULTS: 43.4% changed travel habits since onset of OAT with 24.9% and 18.5% reporting decreased or increased travel activity, respectively. Long-distance worldwide before OAT or having suffered from thromboembolic complications was associated with reduced travel activity. Increased travel activity was associated with more intensive travel experience, increased duration of OAT, higher education, or performing patient self-management (PSM). Travel-associated haemorrhages or thromboembolic complications were reported by 6.5% and 0.9% of the patients, respectively. Former thromboembolic complications, former bleedings and PSM were significant predictors of travel-associated complications.CONCLUSIONS: OAT also increases travel intensity. Specific medical advice prior travelling to prevent complications should be given especially to patients with former bleedings or thromboembolic complications and to those performing PSM.
AB - BACKGROUND: Travel-related conditions have impact on the quality of oral anticoagulation therapy (OAT) with vitamin K-antagonists. No predictors for travel activity and for travel-associated haemorrhage or thromboembolic complications of patients on OAT are known.METHODS: A standardised questionnaire was sent to 2500 patients on long-term OAT in Austria, Switzerland and Germany. 997 questionnaires were received (responder rate 39.9%). Ordinal or logistic regression models with travel activity before and after onset of OAT or travel-associated haemorrhages and thromboembolic complications as outcome measures were applied.RESULTS: 43.4% changed travel habits since onset of OAT with 24.9% and 18.5% reporting decreased or increased travel activity, respectively. Long-distance worldwide before OAT or having suffered from thromboembolic complications was associated with reduced travel activity. Increased travel activity was associated with more intensive travel experience, increased duration of OAT, higher education, or performing patient self-management (PSM). Travel-associated haemorrhages or thromboembolic complications were reported by 6.5% and 0.9% of the patients, respectively. Former thromboembolic complications, former bleedings and PSM were significant predictors of travel-associated complications.CONCLUSIONS: OAT also increases travel intensity. Specific medical advice prior travelling to prevent complications should be given especially to patients with former bleedings or thromboembolic complications and to those performing PSM.
U2 - 10.1016/j.tmaid.2014.02.006
DO - 10.1016/j.tmaid.2014.02.006
M3 - SCORING: Journal article
C2 - 24657200
VL - 12
SP - 258
EP - 263
JO - TRAVEL MED INFECT DI
JF - TRAVEL MED INFECT DI
SN - 1477-8939
IS - 3
ER -